Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.
Autores de IDIVAL
Autores ajenos al IDIVAL
- Gonzalez-Cao M
- Berciano-Guerrero MÁ
- Muñoz-Couselo E
- Manzano JL
- Cerezuela-Fuentes P
- Crespo G
- Soria A
- de Miguel PA
- Gutiérrez Sanz L
- de la Rosa CA
- Puértolas T
- Espinosa E
- Medina J
- Bellido L
- Berrocal A
- Majem M
- López Castro R
- Fernandez LA
- Garcia F
- de la Borbolla MR
- Martín Algarra S
- Márquez-Rodas I
Unidades
Abstract
BACKGROUND: Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population. OBJECTIVE: To analyze the activity of immunotherapy in patients diagnosed with AM in Spain. METHODS: We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry. RESULTS: 69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97-8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32-39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034). CONCLUSIONS: Our data confirms a poor outcome of AM in the Spanish population.
© 2025. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 645-653
- PubMed:
- 40841506
CLINICAL & TRANSLATIONAL ONCOLOGY SPRINGER INT PUBL AG
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- Acral melanoma; Anti PD-1 Ab; Real world data
Campos de Estudio
Cita
Gonzalez M, Berciano MÁ, Muñoz E, Manzano JL, Cerezuela P, Crespo G, Soria A, de Miguel PA, Gutiérrez L, de la Rosa CA, García A, Puértolas T, Espinosa E, Medina J, Bellido L, Berrocal A, Majem M, López R, Fernandez LA, Garcia F, de la Borbolla MR, Martín S, Márquez I. Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry. Clin Transl Oncol. 2025. 28. (2):p. 645-653. IF:2,500. (3).
Actividad Investigadora